(Reuters) - Directors from each company and shareholders of Ilypsa have
approved the proposed acquisition. The deal should close by the
third quarter of 2007, the companies said.
Santa Clara, California-based Ilypsa's lead experimental
drug candidate is ILY101, which is designed to treat
hyperphosphatemia in chronic kidney disease in patients on
hemodialysis.
Read more at Reuters.com Mergers News
approved the proposed acquisition. The deal should close by the
third quarter of 2007, the companies said.
Santa Clara, California-based Ilypsa's lead experimental
drug candidate is ILY101, which is designed to treat
hyperphosphatemia in chronic kidney disease in patients on
hemodialysis.
Read more at Reuters.com Mergers News
No comments:
Post a Comment